On Tuesday, Firstmerit Corp(NASDAQ:FMER)’s shares declined -4.79% to $17.10.
FirstMerit Corporation (FMER) declared that its Board of Directors has declared a dividend of $14.69 per share, or $0.36725 per depository share, on the Company’s 5.875% non-cumulative perpetual preferred stock, Series A, payable November 4, 2015, to shareholders of record on October 20, 2015.
FirstMerit Corporation operates as the bank holding company for FirstMerit Bank N.A. that provides various banking, fiduciary, financial, insurance, and investment services to corporate, institutional, and individual customers. The company’s Commercial segment offers commercial term loans, revolving credit arrangements, asset-based lending, leasing, commercial mortgages, real estate construction lending, and letters of credit, in addition to treasury administration, government banking, international banking, merchant card, and other depository products and services. Its Retail segment provides retail financial products and services, counting consumer direct and indirect installment loans, debit and credit cards, debit gift cards, residential mortgage loans, home equity loans and lines of credit, deposit products, fixed and variable annuities, and ATM network services. This segment also offers deposit products comprising checking, savings, and money market accounts, in addition to certificates of deposit.
MiMedx Group Inc(NASDAQ:MDXG)’s shares dropped -4.12% to $9.31.
MiMedx Group, Inc. (MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, declared recently that its latest peer-reviewed scientific study, “Dehydrated Human Amnion/Chorion Membrane Regulates Stem Cell Activity In Vitro,” was electronically published in the Journal of Biomedical Materials Research: Part B – Applied Biomaterials.
The electronic publication of the peer-reviewed article is now accessible in the Wiley Online Library and can be found at http://onlinelibrary.wiley.com/doi/10.1002/jbm.b.33478/abstract. The paper was authored by Michelle Massee; Kathryn Chinn; Jennifer Lei; Jeremy J. Lim, PhD; Conan S. Young, PhD; and Thomas J. Koob, PhD. The hard copy publication is predictable to follow in a future issue of the Journal of Biomedical Materials Research: Part B – Applied Biomaterials.
MiMedx Group, Inc. develops, processes, and markets patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Its biomaterial platform technologies are AmnioFix, EpiFix, and CollaFix. The company’s AmnioFix and EpiFix are tissue technologies processed from human amniotic membrane derived from donated placentas.
At the end of Tuesday ‘s trade, Illumina, Inc.(NASDAQ:ILMN)‘s shares dipped -2.27% to $193.13.
Illumina, Inc. (ILMN) declared Illumina Accelerator—the world’s first business accelerator focused solely on creating an innovation ecosystem for the genomics industry—has selected three new startups for its second funding cycle. Selected from a competitive pool of highly qualified applicants, the new startups from across the globe are spurring genomics innovation in healthcare, agriculture, and the winemaking industry.
The selected startups for the spring 2015 funding cycle are:
- PathoGn, Inc. is an infectious disease platform company based in California using genomics and machine learning to build pathogen diagnostics and disease forecasting products for agricultural applications.
- Biome Makers Inc. is a microbiome company founded by The Wine Guys, from Castile and Leon, Spain, introducing advanced genomics in the wine sector to transform the quality standards of vinification.
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company’s products comprise sequencing platforms that are based on its SBS technology, which provides researchers with various ranges of applications and the ability to sequence mammalian genomes; and array platforms comprise of HiScan and iScan systems, in addition to NextSeq 550 system that are array scanners for DNA and RNA analysis applications, counting single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis.
Criteo SA (ADR)(NASDAQ:CRTO), ended its Tuesday ‘s trading session with -5.30% loss, and closed at $37.13.
Criteo S.A. (CRTO), the performance marketing technology company, declared that Benoit Fouilland, CFO, will present at the Deutsche Bank Technology Conference, to be held at the Cosmopolitan of Las Vegas, NV on Wednesday, September 16, 2015 at 1:20 pm Pacific Time / 4:20 pm Eastern Time.
Criteo S.A., a technology company, engages in the digital performance marketing in France and internationally. The company leverages granular data to engage and convert customers on behalf of its advertiser clients. Its Criteo Engine solution comprises prediction algorithms that predict the probability and nature of a user’s engagement with a given advertisement; and recommendation algorithms that create and tailor advertisements to specific user interest through modifying the advertisement’s creative content and presentation, and determining the specific products and services to comprise in the advertisement.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
